Pilot phase II, open-label, multicenter, efficacy and safety study of 852A administered intravenously to subjects with unresectable metastatic cutaneous melanoma.
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2011
At a glance
- Drugs 852A (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms 852A-IV-NA-LI-04-MC-M
- Sponsors Pfizer
- 13 Nov 2005 New trial record.